Open AccessAtezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study
Author(s) -
Rie Sugimoto,
Takeaki Satoh,
Akihiro Ueda,
Takeshi Senju,
Yuki Tanaka,
Shunsuke Yamashita,
Toshimasa Koyanagi,
T Kurashige,
Nobito Higuchi,
Tsukasa Nakamura,
Masanori Tanaka,
Yuuki Azuma,
Akari Ohno,
Aritsune Ooho,
Mari Ooe,
Taiji Mutsuki,
Koutarou Uchimura,
Masami Kuniyoshi,
Seiya Tada,
Yoshifusa Aratake,
Tsuyoshi Yoshimoto,
Naoki Yamashita,
Shigeru Harada,
Makoto Nakamuta,
Kenta Motomura,
Motoyuki Kohjima
Publication year - 2022
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000030871
Subject(s) - atezolizumab , bevacizumab , medicine , lenvatinib , oncology , hepatocellular carcinoma , ramucirumab , sorafenib , adverse effect , regorafenib , phases of clinical research , nivolumab , clinical trial , chemotherapy , cancer , colorectal cancer , immunotherapy